Connection

Nigel Temperton to Antibodies, Viral

Back to Details
This is a "connection" page, showing publications Nigel Temperton has written about Antibodies, Viral.
Nigel Temperton
Connection Strength
0.272
Antibodies, Viral
  1. Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg Infect Dis. 2005 Mar; 11(3):411-6.
    View in: PubMed
    Score: 0.029
  2. Coronavirus Pseudotypes for All Circulating Human Coronaviruses for Quantification of Cross-Neutralizing Antibody Responses. Viruses. 2021 08 10; 13(8).
    View in: PubMed
    Score: 0.023
  3. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021 08 05; 184(16):4220-4236.e13.
    View in: PubMed
    Score: 0.023
  4. Comparison of Serological Assays for the Detection of SARS-CoV-2 Antibodies. Viruses. 2021 04 20; 13(4).
    View in: PubMed
    Score: 0.022
  5. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature. 2021 05; 593(7857):136-141.
    View in: PubMed
    Score: 0.022
  6. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. Cell. 2021 04 01; 184(7):1821-1835.e16.
    View in: PubMed
    Score: 0.022
  7. The antigenic anatomy of SARS-CoV-2 receptor binding domain. Cell. 2021 04 15; 184(8):2183-2200.e22.
    View in: PubMed
    Score: 0.022
  8. Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. Euro Surveill. 2020 10; 25(42).
    View in: PubMed
    Score: 0.021
  9. Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines. Front Immunol. 2018; 9:2312.
    View in: PubMed
    Score: 0.019
  10. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Vaccine. 2017 06 27; 35(30):3780-3788.
    View in: PubMed
    Score: 0.017
  11. T cell responses to whole SARS coronavirus in humans. J Immunol. 2008 Oct 15; 181(8):5490-500.
    View in: PubMed
    Score: 0.009
  12. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021 04; 592(7853):277-282.
    View in: PubMed
    Score: 0.005
  13. Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Sci Immunol. 2020 12 23; 5(54).
    View in: PubMed
    Score: 0.005
  14. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. Transfus Med. 2021 Jun; 31(3):167-175.
    View in: PubMed
    Score: 0.005
  15. Development of immunohistochemistry and in situ hybridisation for the detection of SARS-CoV and SARS-CoV-2 in formalin-fixed paraffin-embedded specimens. Sci Rep. 2020 12 14; 10(1):21894.
    View in: PubMed
    Score: 0.005
  16. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020 12; 5(12):1598-1607.
    View in: PubMed
    Score: 0.005
  17. Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays. Viruses. 2020 09 10; 12(9).
    View in: PubMed
    Score: 0.005
  18. Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant. Cell Rep Med. 2020 09 22; 1(6):100099.
    View in: PubMed
    Score: 0.005
  19. Integrase Defective Lentiviral Vector as a Vaccine Platform for Delivering Influenza Antigens. Front Immunol. 2018; 9:171.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.